Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study

Genitourinary Cancer

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial

Lancet Oncol

Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, Kancherla K, Loblaw A, Naismith O, Jain S, Martin A, Price D, Brand D, Chu W, Duffton A, Kelly P, O'Neill B, Staffurth J, Sasso G, Pugh J, Manning G, Brown S, Burnett S, Griffin C, Hall E, van As N, PACE Investigators

doi: 10.1016/S1470-2045(25)00205-0

Genitourinary Cancer

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

Cancer Epidemiol Biomarkers Prev

Farazi M, Yang X, Gehl CJ, Barnett GC, Burnet NG, Chang-Claude J, Parker CC, Dunning AM, Azria D, Choudhury A, Rancati T, De Ruysscher D, Seibold P, Sperk E, Talbot CJ, Veldeman L, Webb AJ, Elliott R, Aguado-Barrera ME, Carballo AM, Fuentes-Ríos O, Gómez-Caamaño A, Peleteiro P, Vega A, Ostrer H, Rosenstein BS, Saito S, Parliament M, Usmani N, Marples B, Chen Y, Morrow G, Messing E, Janelsins MC, Hall W, West CML, Auer PL, Kerns S

doi: 10.1158/1055-9965.EPI-24-1228

Genitourinary Cancer

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials

Lancet Oncol

Nikitas J, Jamshidian P, Tree AC, Hall E, Dearnaley D, Michalski JM, Lee WR, Nguyen PL, Sandler HM, Catton CN, Lukka HR, Incrocci L, Heemsbergen W, Pos FJ, Roy S, Malone S, Horwitz E, Wong JK, Arcangeli S, Sanguineti G, Romero T, Sun Y, Steinberg ML, Valle LF, Weidhaas JB, Spratt D, Telesca D, Kishan AU

doi: 10.1016/S1470-2045(24)00720-4

Genitourinary Cancer

Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial

Eur Urol

Kishan AU, Lamb JM, Wilhalme H, Casado M, Chong N, Zello L, Juarez JE, Jiang T, Neilsen BK, Low DA, Yang Y, Neylon J, Basehart V, Martin Ma T, Valle LF, Cao M, Steinberg ML

doi: 10.1016/j.eururo.2024.10.026

Head and Neck Cancer

Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors

Eur J Cancer

Salvestrini V, Bonaparte I, Becherini C, Desideri I, Caini S, Palomba A, Bertini N, Mattioli C, Simontacchi G, Francolini G, Greto D, Loi M, Di Cataldo V, Livi L, Bonomo P

doi: 10.1016/j.ejca.2025.115260

Skin Cancer

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

Eur J Cancer

Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch ML, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPD, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA

doi: 10.1016/j.ejca.2025.115567

Breast Cancer

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Int J Cancer

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D

doi: 10.1002/ijc.35432

ESMO 2025

Genitourinary Cancer

SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy demonstrates long-term efficacy with minimal toxicity in patients with stage IIA/B seminoma

Lung, Respiratory and Thoracic Cancer

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Clin Cancer Res

Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM

doi: 10.1158/1078-0432.CCR-24-2990

Related content

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials

Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial

Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy demonstrates long-term efficacy with minimal toxicity in patients with stage IIA/B seminoma

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer